Agilent (A) Stock Forecast & Price Target

Compare

3,290 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

A Analyst Ratings

Strong Buy

11 Buy

2 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Agilent

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

A Stock 12 Month Forecast

Average Price Target

$167.50

▲(14.79% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Agilent in the last 3 months. The average price target is $167.50 with a high forecast of $180.00 and a low forecast of $130.00. The average price target represents a 14.79% change from the last price of $145.92.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"104":"$104","181":"$181","123.25":"$123.3","142.5":"$142.5","161.75":"$161.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":167.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$167.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$130.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[104,123.25,142.5,161.75,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.827,139.22492307692306,142.62284615384615,146.02076923076922,149.4186923076923,152.81661538461537,156.21453846153847,159.61246153846153,163.01038461538462,166.4083076923077,169.80623076923078,173.20415384615384,176.60207692307694,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.827,138.2633846153846,140.69976923076922,143.13615384615383,145.57253846153847,148.00892307692308,150.4453076923077,152.8816923076923,155.31807692307692,157.75446153846153,160.19084615384617,162.62723076923078,165.0636153846154,{"y":167.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,135.827,135.37876923076922,134.93053846153845,134.4823076923077,134.03407692307692,133.58584615384615,133.13761538461537,132.68938461538463,132.24115384615385,131.79292307692307,131.3446923076923,130.89646153846155,130.44823076923078,{"y":130,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":133.267,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.898,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.379,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.834,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.397,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.994,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.184,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.332,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.098,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.832,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.827,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$180.00

Average Price Target$167.50

Lowest Price Target$130.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Daniel Brennan

TD Cowen

$170

Buy

16.50%

Upside

Reiterated

01/07/26

Analysts Are Bullish on Top Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Agilent (A)

Patrick B Donnelly

Citi

$124.2→

Buy

―

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A) and Tenet Healthcare (NYSE: THC)

Vijay Kumar

Evercore ISI

$155→$160

Buy

9.65%

Upside

Upgraded

01/05/26

Agilent upgraded to Outperform from In Line at Evercore ISIAgilent upgraded to Outperform from In Line at Evercore ISI

Luke Sergott

Barclays

$165

Buy

13.08%

Upside

Reiterated

12/19/25

Barclays Remains a Buy on Agilent (A)

Daniel Arias

Stifel Nicolaus

$170

Buy

16.50%

Upside

Reiterated

12/11/25

Evie Koslosky

Goldman Sachs

$170

Buy

16.50%

Upside

Initiated

12/09/25

Agilent initiated with a Buy at Goldman SachsAgilent initiated with a Buy at Goldman Sachs

Kallum Titchmarsh

Morgan Stanley

$180

Buy

23.36%

Upside

Initiated

12/03/25

Agilent initiated with an Overweight at Morgan StanleyAgilent initiated with an Overweight at Morgan Stanley

Brandon Couillard

Wells Fargo

$150→$175

Buy

19.93%

Upside

Reiterated

11/25/25

Wells Fargo Reaffirms Their Buy Rating on Agilent (A)

Dan Leonard

UBS

$170→$180

Buy

23.36%

Upside

Reiterated

11/25/25

Agilent price target raised to $180 from $170 at UBSAgilent price target raised to $180 from $170 at UBS

Catherine Ramsey Schulte

Robert W. Baird

$142→$165

Buy

13.08%

Upside

Reiterated

11/25/25

Agilent price target raised to $165 from $142 at BairdAgilent price target raised to $165 from $142 at Baird

Michael Ryskin

Bank of America Securities

$130→$165

Hold

13.08%

Upside

Reiterated

11/24/25

Agilent Technologies: Balanced Outlook with Hold Rating Amid Mixed Financial Signals

Casey Woodring

J.P. Morgan

$165→$180

Buy

23.36%

Upside

Reiterated

11/24/25

Agilent price target raised to $180 from $165 at JPMorganAgilent price target raised to $180 from $165 at JPMorgan

Tycho Peterson

Jefferies

$130

Hold

-10.91%

Downside

Reiterated

10/17/25

Agilent (A) Gets a Hold from Jefferies

Natalya Davies

Rothschild & Co Redburn

$165

Buy

13.08%

Upside

Initiated

10/08/25

Agilent initiated with a Buy at Rothschild & Co RedburnAgilent initiated with a Buy at Rothschild & Co Redburn

Puneet Souda

Leerink Partners

$135→$140

Buy

-4.06%

Downside

Reiterated

09/01/25

Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A) and Edwards Lifesciences (NYSE: EW)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Daniel Brennan

TD Cowen

$170

Buy

16.50%

Upside

Reiterated

01/07/26

Analysts Are Bullish on Top Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Agilent (A)

Patrick B Donnelly

Citi

$124.2→

Buy

―

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A) and Tenet Healthcare (NYSE: THC)

Vijay Kumar

Evercore ISI

$155→$160

Buy

9.65%

Upside

Upgraded

01/05/26

Agilent upgraded to Outperform from In Line at Evercore ISIAgilent upgraded to Outperform from In Line at Evercore ISI

Luke Sergott

Barclays

$165

Buy

13.08%

Upside

Reiterated

12/19/25

Barclays Remains a Buy on Agilent (A)

Daniel Arias

Stifel Nicolaus

$170

Buy

16.50%

Upside

Reiterated

12/11/25

Evie Koslosky

Goldman Sachs

$170

Buy

16.50%

Upside

Initiated

12/09/25

Agilent initiated with a Buy at Goldman SachsAgilent initiated with a Buy at Goldman Sachs

Kallum Titchmarsh

Morgan Stanley

$180

Buy

23.36%

Upside

Initiated

12/03/25

Agilent initiated with an Overweight at Morgan StanleyAgilent initiated with an Overweight at Morgan Stanley

Brandon Couillard

Wells Fargo

$150→$175

Buy

19.93%

Upside

Reiterated

11/25/25

Wells Fargo Reaffirms Their Buy Rating on Agilent (A)

Dan Leonard

UBS

$170→$180

Buy

23.36%

Upside

Reiterated

11/25/25

Agilent price target raised to $180 from $170 at UBSAgilent price target raised to $180 from $170 at UBS

Catherine Ramsey Schulte

Robert W. Baird

$142→$165

Buy

13.08%

Upside

Reiterated

11/25/25

Agilent price target raised to $165 from $142 at BairdAgilent price target raised to $165 from $142 at Baird

Michael Ryskin

Bank of America Securities

$130→$165

Hold

13.08%

Upside

Reiterated

11/24/25

Agilent Technologies: Balanced Outlook with Hold Rating Amid Mixed Financial Signals

Casey Woodring

J.P. Morgan

$165→$180

Buy

23.36%

Upside

Reiterated

11/24/25

Agilent price target raised to $180 from $165 at JPMorganAgilent price target raised to $180 from $165 at JPMorgan

Tycho Peterson

Jefferies

$130

Hold

-10.91%

Downside

Reiterated

10/17/25

Agilent (A) Gets a Hold from Jefferies

Natalya Davies

Rothschild & Co Redburn

$165

Buy

13.08%

Upside

Initiated

10/08/25

Agilent initiated with a Buy at Rothschild & Co RedburnAgilent initiated with a Buy at Rothschild & Co Redburn

Puneet Souda

Leerink Partners

$135→$140

Buy

-4.06%

Downside

Reiterated

09/01/25

Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A) and Edwards Lifesciences (NYSE: EW)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agilent

3 Months

xxx

Success Rate

17/25 ratings generated profit

Average Return

+5.04%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.00% of your transactions generating a profit, with an average return of +5.04% per trade.

1 Year

Brandon CouillardWells Fargo

Success Rate

32/40 ratings generated profit

Average Return

+19.46%

reiterated a buy rating 2 months ago

Copying Brandon Couillard's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +19.46% per trade.

2 Years

xxx

Success Rate

33/42 ratings generated profit

Average Return

+21.57%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 78.57% of your transactions generating a profit, with an average return of +21.57% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

A Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, A has received 22 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. A average Analyst price target in the past 3 months is 167.50.

Each month's total comprises the sum of three months' worth of ratings.

A Financial Forecast

A Earnings Forecast

Next quarter’s earnings estimate for A is $1.37 with a range of $1.36 to $1.38. The previous quarter’s EPS was $1.59. A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year A has Performed in-line its overall industry.

A Sales Forecast

Next quarter’s sales forecast for A is $1.81B with a range of $1.79B to $1.82B. The previous quarter’s sales results were $1.86B. A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year A has Performed in-line its overall industry.

A Stock Forecast FAQ

What is A’s average 12-month price target, according to analysts?

Based on analyst ratings, Agilent’s 12-month average price target is 167.50.

What is A’s upside potential, based on the analysts’ average price target?

Agilent has 14.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is A a Buy, Sell or Hold?

Agilent has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.

What is Agilent’s price target?

The average price target for Agilent is 167.50. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $180.00 ,the lowest forecast is $130.00. The average price target represents 14.79% Increase from the current price of $145.92.

What do analysts say about Agilent?

Agilent’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of A?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Agilent (A) Stock Forecast & Price Target

A Analyst Ratings

A Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Agilent

A Analyst Recommendation Trends

A Financial Forecast

A Earnings Forecast

A Sales Forecast

A Stock Forecast FAQ

Detailed List of Analyst Forecasts